Prof. Nicolas Girard joined us at the European Lung Cancer Conference (ELCC) 2025 to share his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at the congress.
Prof. Girard reviews data from the following studies:
- SOHO-01: Phase 1/2 SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts. Girard N, et al. Abstract 3O, ELCC 2025
- MARIPOSA: Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: Final overall survival from the Phase 3 MARIPOSA study. Chih-Hsin Yang J, et al. Abstract 4O, ELCC 2025
- COCOON: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial. Girard N, et al. Abstract 10MO, ELCC 2025
- SAVANNAH: Savolitinib + osimertinib in patients with EGFRm advanced NSCLC and MET overexpression and/or amplification following progressive disease on osimertinib. Ahn M-J, et al. Abstract 2O, ELCC 2025
- ORCHARD: Osimertinib + datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC whose disease progressed on first-line osimertinib: ORCHARD. Le X, et al. Abstract 1O, ELCC 2025
- DESTINY-Lung03: Phase 1b open-label study of trastuzumab deruxtecan + rilvegostomig ± carboplatin as first-line treatment for metastatic HER2-overexpressing NSCLC: DESTINY-Lung03 (DL-03) Part 4. Planchard D, et al. 132TiP, ELCC 2025
Watch his short summary video and download the accompanying slides for a more detailed update.
Clinical takeaways
- SOHO-01: Treatment with BAY 2927088 led to durable responses in HER2m NSCLC patients naïve to HER2-targeted therapy and in those who had received a HER2-targeted ADC
- MARIPOSA: A highly meaningful and practice changing OS benefit was observed, further establishing amivantamab plus lazertinib as a new standard of care in patients with first-line EGFRm advanced NSCLC
- COCOON: Early onset AEs experienced with amivantamab plus lazertinib treatment can be significantly reduced with proactive prophylactic approaches
- SAVANNAH: Savolitinib plus osimertinib may offer a chemotherapy-free treatment option in patients with EGFRm, MET overexpressed and/or amplified advanced NSCLC after progression on osimertinib
- ORCHARD: Osimertinib plus Dato-DXd showed promising efficacy and manageable safety in patients with EGFRm advanced NSCLC who progressed on first-line osimertinib
- DESTINY-Lung03: a trial in progress investigating T-DXd plus rilvegostomig ± carboplatin as first-line therapy for resectable, advanced or metastatic HER2-overexpressing NSCLC
Download Slides - PDF 
Duration
Language(s)
Downloadable 
MIN
May 2025 
